InvestorsHub Logo
Followers 438
Posts 18533
Boards Moderated 0
Alias Born 09/10/2000

Re: None

Friday, 02/09/2024 7:25:44 PM

Friday, February 09, 2024 7:25:44 PM

Post# of 3267
Warrington-based Windtree Therapeutics is currently exploring strategic alternatives to enhance shareholder value, including the possibility of acquisitions or being acquired, writes John George for the Philadelphia Business Journal.

The company has enlisted the services of Ladenburg Thalmann & Co. Inc. to assess its options.

Despite a challenging financial landscape, Windtree has taken significant steps to bolster its financial standing. These include a lucrative licensing agreement potentially worth over $138 million and the elimination of a $15 million contingent liability.

The Dog that doesn't bark is the one to pay attention to

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent WINT News